TOP2/YNL088W Literature Guide Help

Other names published for TOP2: TOR3, TRF3, DNA topoisomerase 2, YNL088W

TOP2 - Non-Fungal Related Genes/Proteins (62)

Results: 1 - 30 of 62 records
   1  2  3 
ReferenceOther Genes Addressed
Aves SJ, et al.  (2012) Evolutionary diversification of eukaryotic DNA replication machinery. Subcell Biochem 62():19-35
Joshi RS, et al.  (2012) Topoisomerase II is required for the production of long Pol II gene transcripts in yeast. Nucleic Acids Res 40(16):7907-15
Schmidt BH, et al.  (2012) Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity. Nat Struct Mol Biol 19(11):1147-54
On T, et al.  (2010) The evolutionary landscape of the chromatin modification machinery reveals lineage specific gains, expansions, and losses. Proteins 78(9):2075-89
D'Ambrosio C, et al.  (2008) Condensin-Dependent rDNA Decatenation Introduces a Temporal Pattern to Chromosome Segregation. Curr Biol 18(14):1084-9
Meczes EL, et al.  (2008) The impact of the human DNA topoisomerase II C-terminal domain on activity. PLoS ONE 3(3):e1754
Wilstermann AM, et al.  (2007) Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Biochemistry 46(28):8217-25
Lourenco EE, et al.  (2006) Molecular characterization of type II topoisomerase in the endosymbiont-bearing Trypanosomatid Blastocrithidia culicis. FEMS Microbiol Lett 257(1):163-70
Mouchel NA and Jenkins JR  (2006) The identification of a functional interaction between PKC and topoisomerase II. FEBS Lett 580(1):51-7
de Mejia EG, et al.  (2006) Catalytic inhibition of human DNA topoisomerase by phenolic compounds in Ardisia compressa extracts and their effect on human colon cancer cells. Food Chem Toxicol 44(8):1191-203
Hellauer K, et al.  (2005) Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae. Mol Pharmacol 68(5):1365-75
Vaughn J, et al.  (2005) Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis. J Biol Chem 280(12):11920-9
Hossain MS, et al.  (2004) DNA topoisomerase II is required for the G0-to-S phase transition in Drosophila Schneider cells, but not in yeast. Genes Cells 9(10):905-17
Moro S, et al.  (2004) Interaction model for anthracycline activity against DNA topoisomerase II. Biochemistry 43(23):7503-13
Suda N, et al.  (2004) The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity. Nucleic Acids Res 32(5):1767-73
Hanke T, et al.  (2003) Cloning, functional analysis and post-transcriptional regulation of a type II DNA topoisomerase from Leishmania infantum. A new potential target for anti-parasite drugs. Nucleic Acids Res 31(16):4917-28
Marshall KM, et al.  (2003) The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine. Biochem Pharmacol 66(3):447-58
Sengupta T, et al.  (2003) Functional dissection of the C-terminal domain of type II DNA topoisomerase from the kinetoplastid hemoflagellate Leishmania donovani. Nucleic Acids Res 31(18):5305-16
Singh BN, et al.  (2003) Molecular characterization of a nuclear topoisomerase II from Nicotiana tabacum that functionally complements a temperature-sensitive topoisomerase II yeast mutant. Plant Mol Biol 52(5):1063-76
Suda N, et al.  (2003) Function of the loop residue Thr792 in human DNA topoisomerase II alpha. Biochem Biophys Res Commun 303(1):46-51
Vilain N, et al.  (2003) Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha. Nucleic Acids Res 31(19):5714-22
Strumberg D, et al.  (2002) Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action. Antimicrob Agents Chemother 46(9):2735-46
Trigueros S and Roca J  (2002) A GyrB-GyrA fusion protein expressed in yeast cells is able to remove DNA supercoils but cannot substitute eukaryotic topoisomerase II. Genes Cells 7(3):249-57
Trigueros S and Roca J  (2002) Failure to relax negative supercoiling of DNA is a primary cause of mitotic hyper-recombination in topoisomerase-deficient yeast cells. J Biol Chem 277(40):37207-11
Byl JA, et al.  (2001) DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry 40(3):712-8
Heddle JG, et al.  (2001) The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. J Mol Biol 307(5):1223-34
Okada Y, et al.  (2001) Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene 272(1-2):141-8
Sakaguchi A, et al.  (2001) A distinct subnuclear localization of mammalian DNA topoisomerase IIbeta in yeast. Biochem Biophys Res Commun 283(4):876-82
Jensen LH, et al.  (2000) A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J Biol Chem 275(3):2137-46
Okada Y, et al.  (2000) Assignment of functional amino acids around the active site of human DNA topoisomerase IIalpha. J Biol Chem 275(32):24630-8
Results: 1 - 30 of 62 records
   1  2  3